Thanks, Ming.
we been the This the first the testing processed last against the our efforts X in we what the first signs proud one of new setting the year. we same tools volume processed we proud tests. to of Since accomplished of RT-PCR are quarter, has XXXx company, records is the in first our quarter, over the equally fight fight total the financial time, virus, In for company's same SARS-CoV-X. are roughly and the of at of best pandemic. million We numerous quarter
to like as have resources new meet think to in said, states testing Fulgent That of time with surges scale, quality team's are played plateaued deploy at and and we we With efforts still turnaround the United our appear level, results high to continue to but the a number States. the dealing cases improvement. some our country's deliver across relentless down, cases role meaningful small lab a
saw While business. a COVID-XX quarter, strong in next-generation sequencing we the first in terms testing in very we performance demonstrated record of our also
paradigm XXX%. to NGS year-over-year of continued grew growth tests to XX,XXX and company. million in has markets R&D from shift. reproductive increase for compared most million a With first representing of our been Meaning service. bit in to XXX% an year, pediatric the XX,XXX COVID-XX launch Our last of traditional a tests, hereditary includes sequencing $X.X disease genetics, a This $XX.X of more The outside was volume hereditary partnerships as the seeing sales normal a and investments we and to clients beginning are new our driven opportunities run of diseases of strategic our return a has organization. made new number our cardiovascular commercial our continued biopharma create we menu to to in in traction cases decreasing, adult growth and health with cancer, rate, rare business by quarter new new neurogenetics,
not this to to RT-PCR standard gold cetera, office, testing we positions to the We time travel, are begin return rapid As testing testing. are as in test of or our scale seeing return programs at screening to testing to the to shows events, test the evidence molecular us allowing normalcy turnaround perfectly less delivering shift be of and address used now history Several than believe people of attend population sensitive be Many to less demand. operations et our employers. include with antigen schools rapid sensitivity larger RT-PCR. asymptomatic
schools New Vegas about Las City York on and talked previous have calls. We schools
to continue successful We enabling been effective minimize there positives, screen isolation and many detecting in students spread. have to
are We test picture families at-home meaningful seen play test their send able to to also kits our have we for continued monitoring. a role home as
estimated tests up new this million the is over ramp billion to time, and be the from new to in and the COVID-XX Regarding It schools this was hear Human be as we to response rolled of President students more return the it will New mid-March, program $XX out. we National plan of additional students pipeline Department per are additional across announced X City will of our testing even testing that needed program. of U.S. schools At part to School in-person have future sales as Health schools thousands preparedness, with Rescue HHS, call now Testing we many for and plans specifically, help invest per await processing day as Services for actively American learning. new are national York hundreds will Biden's onboarding and day pandemic In strategy reopen. the schools in how
take for volume. program these intersection contract provide quarter, and During we the strains important mutations, NGS laboratory sequencing to have this to had COVID-XX of CDC CDC funding played competencies, surveillance, national emerging we or spotlight of an pandemic hit massive in entering information perfect fourth quarter to in that new COVID-XX and Fulgent's variants. for support a level the next-generation our for first to lines primed important responses ability Such to to to surveillance mutations we new and due million announce public a in earnings monumental core we screen variants and identifying awarded and privilege and its defining for ready the $XX mentioned identify call, studies genomic and improving and state testing genomic data. unusual [Technical were track health Along the new with and surveys on SARS-CoV-X. identify national the changes ultimately, decision-making viral transmission, Difficulty] better up role to essential with large-scale baseline potential
we pilot the Coast B.X.XXX Before variants were program, the initiated emerging as February, in were quickly in studies. a our with California. and early as B.X.XXX variants public CDC. already confirmed had identified Important also X such concerns These discoveries, variants in award pilot partnering the health by X surveillance West of laboratories
workflows and Coast the for sequencing timely bioinformatic study helped public Our surveillance limited baseline laboratories access complexity samples a the issues of and with the health West the and pilot good set and analysis. to sequencing remnant overcome for on
partnership, contact look to the With our Biden transmission. Plan in the the can And this deployed San the COVID-XX has American CDC lab first control mid-April, variants. we of sequencing be We labs of in from have from thousands community the are prioritize travel, to monitor, B.X.XXX CDC States. United $X.X it to workplace its emerging and week would Clara, our that Rescue or collaborator the exposure, epidemiologist either value track part Helping help effective through we Colorado with proven per The other and of P.X variants. in enables identified P.X the of measures the to this At positives fight forward and billion are CDC contract Governors more. fulfilling and Bernardino, with. announced first across sources so additional the the that funding defeat existing opportunities dedicating outbreak successfully efforts transmission. genomic data we was the and any Santa administration in many point, tracing Moreover, in
to Turning capacity.
continue capacity to we Considering of and the handle contracts. our opportunities our efficiencies increase by high as at allow workflows X.XX with size per million the allow of think to this level for K-X some continuing very our tests point, We improve testing can the applications such return time, of -- turnaround normalcy locations, Fulgent will laboratory investment. us will a little National to capacity, between program, At north day. mobile we compete these to X
obtained we During distribution XX-plus from our of vaccines. Los thousands County. tens have authorization underrepresented the quarter, Fulgent of state and in the since administered aid in partnership have California and locations, of Angeles to deployed vaccination first in of the Starting doses with serviced primarily March, fleet in communities mobile
system, fully suite and their platform the vaccination. management their management a using a are Fulgent outset. test vaccination Combined the services reminders execution. to of clients new of platform allowing existing usually clients We request X to allow Fulgent-managed turnaround site take vaccine at schedule present from the location, mobile week newly deployability patients expand find appointment, efforts of with our receive track launched to their rapid full to with is our fleet, This see advantage and operations integrated of to program
of we continue in the areas also of one run invest continue new we operations largest While States, to the in genomics. COVID-XX United to
such areas flow significant biopsy, diagnostics immunohistochemistry. expertise companion liquid can as Fulgent the is cancer combining and our testing, team. excited including cytometry residual lead strategy, renowned capabilities As minimal development traditional believe Weiss and make and to technology product We FISH, and a will as Dr. pathologist, with platform, help Larry strategic Dr. very progress Dr. Ming in join partnerships. are mentioned, and have we Weiss our such oncology Weiss' we disease,
With years, Fulgent we Over in the is, often to the menu do has all the going It's menu invest we which testing. straightforward have Fulgent Dr. been last over to couple receive exploded somatic Weiss expand business to does of A question test intend quickly. genetic tests, our and answer. forward? onboard, how of include fairly test so plan a XX,XXX germline
continue a can in believe are in launch pace, can growth. scale, company, platform, the organically, Since force. services way, continued that believe this be of we not we cost to and to strategic look platforms are able opportunities. of seamlessly menu everything hard record a built actively for relying in we lab say. technology market, With been our we and build for believe we a disruptive more we can new We By operational and third test technology. to structure, we with consolidator doing in markets investing new and underlying to we and founding believers systems at other series our capabilities, so, like acquired organic continue have continue this we market, With the together stitch inefficient, on or be parties even our we've integrated a to acquisitions
are And to scale to our continue we we we sales updated as in we done national have path. hyper would Paul navigate not execute be that, Paul? look as our turn addition, at we Financial a as I growth build growth In to dynamic force, capabilities, we position our expand to Chief the make and With additional can continues strong date. keeping go-to-market on our something our elite to Fulgent call Officer, a sales believe to over out this progress. like forward time We talent recruit believe business. we Kim. investors to It we to a strategy
